Meet the Board

Dr David Mazzo

Dr David Mazzo

Chairman of the Board
Dr Stephen Snowdy

Dr Stephen Snowdy

Chief Executive Officer and Executive Director
Mr Brian Lane

Mr Brian Lane

Chief Financial Officer
Mr Tony Sommer, Jr.

Mr Tony Sommer, Jr.

Senior VP Sales and Marketing
Christi Van Heek

Christi Van Heek

Non-executive Director
Jean Franchi

Jean Franchi

Non-executive Director
Zita Peach

Zita Peach

Non-executive Director
Tom Dooley

Tom Dooley

Non-executive Director

Dr David Mazzo

Chairman of the Board

Dr. David Mazzo is a highly accomplished and experienced life sciences executive and board director with almost 40 years of experience in managing medical device and pharmaceutical companies.

 

Dr. Mazzo is currently President, CEO and Executive Director of Caladrius Biosciences, Inc. (NASDAQ: CLBS). He also serves on the boards of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT), and Seneca Biopharmaceuticals, Inc. (NASDAQ: SNCA). Previously, Dr. Mazzo served as CEO and Executive Director of Regado Biosciences, Inc., where, among other accomplishments, he led Regado’s IPO.

 

Prior to leading Regado, Dr. Mazzo was CEO and Executive Director of Aeterna Zentaris (NASDAQ: AEZS, TSX: AEZS), and of Chugai Pharma USA, LLC, the U.S. subsidiary of Japan’s Chugai Pharmaceuticals Co. Ltd. (TYO: 4519), a member of the Roche group (SWX:RO).  Dr. Mazzo has also had a distinguished international career leading pharmaceutical development for Rhone-Poulenc Rorer and Hoechst Marion Roussel culminating in his position as Senior Vice President of Development Operations for Schering-Plough Research Institute.

 

Dr. Mazzo’s academic training and early career were in analytical chemistry.  He received his Ph.D. degree in Analytical Chemistry from the University of Massachusetts Amherst, and completed a research fellowship at the Ecole Polytechnique Federale de Lausanne in Switzerland.  He earned a BA in the Honors program (interdisciplinary humanities) and a BS in chemistry at Villanova University.

Dr Stephen Snowdy

Chief Executive Officer and Executive Director

Initially joined VTI as Chairman in May 2009 and has been Chief Executive Officer since June 201315 years of experience in life science venture investing and executive managementDoctorate (major in Neurobiology) and Master of Business Administration from the University of North Carolina, and a Bachelor of Science (Major in Chemistry) from the University of Florida.

Mr Brian Lane

Chief Financial Officer

30 years' experience in financial operations and managementPreviously CFO of OnePath, controller for PRGX Global (NASDAQ:PRGX), and has held senior finance roles in other companies in financial services, franchising and manufacturingBachelor of Business Administration from the University of Georgia, and is a Certified Public Accountant (CPA)

Mr Tony Sommer, Jr.

Senior VP Sales and Marketing

20 years' experience in sales and marketing managementPreviously Head of Sales for Bausch & Lomb's US Vision Care divisionBachelor of Science from the United States Air Force Academy and Master of Business Administration from Oklahoma City University

Christi Van Heek

Non-executive Director

Christi has over 25 years of experience in the life sciences industry. She previously served as Vice President of Global Marketing for Genzyme, amongst other roles (acquired by Sanofi S.A. for >US$20bn)Currently she serves on the board of Concert Pharmaceuticals, a NASDAQ listed biotechnology and previously served on the board of Affymax (previously listed on the NASDAQ)

Jean Franchi

Non-executive Director

Jean has 20 years of experience building finance/accounting systems and teams in the life sciences industry.Currently she serves as CFO of Merrimack, a NASDAQ- listed pharmaceutical company and previously served as SVP Corporate Finance at Genzyme, a biotech company with over $4B in revenue, and as CFO of Dimension Therapeutics and Good Start Genetics

Zita Peach

Non-executive Director

With over 30 years of experience in the pharmaceutical, biotechnology, medical device & healthcare sectors, Zita currently serves on the board of ASX-listed Starpharma Holdings, Monash IVF Group and AirXpanders, in addition to board position with Bionic Vision Technologies Pty Ltd.Previously held executive roles at ASX-listed CSL Limited and Fresenius Kabi.

Tom Dooley

Non-executive Director

Tom has 30 years of experience in pharma and medical devices, including contact lenses and eye care.Most recently served as President of Alcon Japan, where he oversaw 1,300 employees, and $1B in revenue from contact lens products, medical devices, and pharma.Previously served as Alcon’s country manager in Australia and New Zealand.